Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04937244
Other study ID # 2021-SE-01
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date May 13, 2021
Est. completion date May 11, 2022

Study information

Verified date June 2021
Source Northwell Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fluorescence-guided resection using 5-ALA induced tumor fluorescence of malignant gliomas allows for better identification of tumor tissue and more radical resection in select patients and improvements in progression-free and overall survival. With new developments in surgical microscopy, the development of digital exoscopes have provided advanced visualization as well as improvements in ergonomics and accessibility of the surgical field. The use of the exoscope in 5-ALA fluorescence-guided tumor surgery has the potential to enhance the ability of the surgeon to remove brain tumors with high efficacy. While algorithms for use of 5-ALA fluorescence have been optimized for use with traditional microscopes, the use of fluorescence techniques in newer digital exoscopes have not been developed. The primary outcome of the study is to obtain parameters to optimize visualization of fluorescence intensity and perform optimization based on the intensities achieved. The operating ORBEYE exoscope will be fitted with a blue light filter. All experiments will be performed in darkened operating rooms. The ORBEYE exoscope will be set up at constant distances from the target and incident light intensities. The focal distance and light intensity settings will be recorded from the data displayed on the microscope. Patients (experimental group) will receive 5ALA treatment before operation, blue light filter imagining will take place after tacking up dura and prior to direct resection. The expected outcomes of image analysis will be to have a set of exoscope parameters optimized for visualization of 5ALA tissue in different tumor types. This 5ALA characterization of visualization parameters has never been completed on an exoscope. Optimizing ORBEYE exoscope parameters will define a standard in glioma resection using 5ALA under a novel exoscopic filter as well as contribute insight into the use of the fluorescent filter for additional tumor types.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date May 11, 2022
Est. primary completion date May 11, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male and female = 18 years of age - Must have a suspected or biopsy-proven glioma (World Health Organization grade II or IV), new or recurrent - Indication for craniotomy for removal of a suspected or recurrent brain tumor - Karnofsky Performance Scale = 60% - Willing and able to provide informed consent or have surrogate consent by legally authorized representative Exclusion Criteria: - Male and female < 18 years of age - Porphyria, hypersensitivity to porphyrins - Renal insufficiency as defined by a creatinine > 2.0 mg/dL - Hepatic insufficiency as diagnosed in preoperative medical clearance evaluation - Females of childbearing potential with a positive pregnancy test - Nursing women - Unwilling or unable to provide informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
5ALA exoscopic fluorescence filter
Visualization of tumor tissue with 5ALA will be done in the operating room to localize neoplastic tissue. The operation will be conducted in a standard fashion uninfluenced by the imaging on the ORBEYE exoscope. The ORBEYE exoscope will be used with the blue light filter after tacking up dura upon first visualization of tumor tissue prior to direct resection. Images will be taken prior to, during and at the end of the planned resection. The ORBEYE exoscope will be set up at constant distances from the target and incident light intensities. The focal distance and light intensity settings will be recorded from the data displayed on the microscope. The ORBEYE exoscope or standard operating microscope (depending on surgeon preference) will then be used in the standard fashion of an operative microscope with a fluorescent filter, to assist with surgical resection as per the surgeon's preference. Resection will proceed according to current standard of care.

Locations

Country Name City State
United States Lenox Hill Hospital New York New York

Sponsors (2)

Lead Sponsor Collaborator
Northwell Health Olympus Corporation

Country where clinical trial is conducted

United States, 

References & Publications (3)

Belykh E, Miller EJ, Patel AA, Bozkurt B, Yagmurlu K, Robinson TR, Nakaji P, Spetzler RF, Lawton MT, Nelson LY, Seibel EJ, Preul MC. Optical Characterization of Neurosurgical Operating Microscopes: Quantitative Fluorescence and Assessment of PpIX Photobleaching. Sci Rep. 2018 Aug 22;8(1):12543. doi: 10.1038/s41598-018-30247-6. — View Citation

Hadjipanayis CG, Widhalm G, Stummer W. What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas? Neurosurgery. 2015 Nov;77(5):663-73. doi: 10.1227/NEU.0000000000000929. Review. — View Citation

Langer DJ, White TG, Schulder M, Boockvar JA, Labib M, Lawton MT. Advances in Intraoperative Optics: A Brief Review of Current Exoscope Platforms. Oper Neurosurg (Hagerstown). 2020 Jul 1;19(1):84-93. doi: 10.1093/ons/opz276. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Focal Distance To characterize optimal focal distance on the 5ALA fluorescence ORBEYE exoscope microscope during glioma removal 6 weeks
Primary Light Intensity To characterize optimal light intensity settings on the 5ALA fluorescence ORBEYE exoscope microscope during glioma removal 6 weeks
Primary Working Angle To characterize optimal working angle position on the 5ALA fluorescence ORBEYE exoscope microscope during glioma removal 6 weeks
Secondary Usability of 5ALA exoscope filter as assessed by overall surgery length To determine functionality and performance reliability of the blue light excitation filter on the ORBEYE exoscope platform with overall surgery length 6 weeks
Secondary Usability of 5ALA exoscope filter as assessed by surgeon qualitative assessment To determine functionality and performance reliability of the blue light excitation filter on the ORBEYE exoscope platform with surgeon qualitative assessment 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03011671 - Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma Phase 1
Recruiting NCT05686798 - Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. Phase 1
Recruiting NCT02617134 - CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor Phase 1/Phase 2
Completed NCT03355794 - A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Phase 1
Recruiting NCT03423992 - Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas Phase 1
Not yet recruiting NCT04482933 - HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma Phase 2
Not yet recruiting NCT06417281 - Photodynamic Diagnosis for Malignant Brain Glioma With 5-Aminolevulinic Acid(5-ALA) Phase 3
Withdrawn NCT03176160 - LITT Palliative Treatment for Patients With Malignant Gliomas
Recruiting NCT02839954 - CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor Phase 1/Phase 2
Recruiting NCT03152318 - A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 Phase 1
Completed NCT00870181 - ADV-TK Improves Outcome of Recurrent High-Grade Glioma Phase 2
Completed NCT01550523 - Pilot Immunotherapy Trial for Recurrent Malignant Gliomas Phase 1
Terminated NCT01017653 - Panitumumab and Irinotecan for Malignant Gliomas Phase 2